Atypical brain maturation in psychosis is associated with long-term cognitive decline and symptom progression

Claudio Alemán-Morillo[1], Natalia García-San-Martín[1], Richard AI Bethlehem[2], Lena Dorfschmidt[3,4], María Alemany-Navarro[5], Patricia Segura[1], Alessia Pasquini[1], Manuel Muñoz Caracuel[6], Manuel Canal Rivero[6], Jakob Seidlitz[3,4,7,8], Rosa Ayesa-Arriola[9], Javier Vázquez-Bourgon[9], John Suckling[10], Miguel Ruiz-Veguilla[6], Benedicto Crespo-Facorro[6,9], Rafael Romero-García[1,10,11].

Author affiliations:

[1]Department of Medical Physiology and Biophysics, University of Seville; Seville, Spain.

[2]Department of Psychology, University of Cambridge; Cambridge, UK.

[3]Department of Child and Adolescent Psychiatry and Behavioral Science, The Children's Hospital of Philadelphia; Philadelphia, PA, USA.

[4]Lifespan Brain Institute, The Children's Hospital of Philadelphia and Penn Medicine; Philadelphia, PA, USA.

[5]Translational Psychiatry Group, Seville Biomedical Research Institute (IBiS)-CSIC; Foundation for Health Research Management in Sevilla, Spain.

[6]Mental Health Service, Virgen del Rocío University Hospital; Seville, Spain. Instituto de Biomedicina de Sevilla (IBiS) HUVR/CSIC/University of Seville / CIBERSAM, ISCIII; Seville, Spain.

[7]Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.

[8]Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA

[9]Department of Psychiatry. Marqués de Valdecilla University Hospital, IDIVAL, School of Medicine, University of Cantabria; Santander, Spain.

[10]Department of Psychiatry, University of Cambridge; Cambridge, UK.

[11]Instituto de Biomedicina de Sevilla (IBiS) HUVR/CSIC/University of Seville / CIBERSAM, ISCIII; Seville, Spain.

Correspondence to: Rafael Romero García
Full address: Avda. Doctor Fedriani S/N, 41009, Seville (Spain)
Telephone: +34 954551768
E-mail: rr480@cam.ac.uk

Running title: Centiles and cognition in psychosis.

Keywords: Psychosis, normative modelling, centiles, cognition, longitudinal MRI, schizophrenia

ABSTRACT

Background: Clinical progression during psychosis has been closely associated with grey matter abnormalities resulting from atypical brain development. However, the complex interplay between psychopathology and neurodiversity challenges identifying neuroanatomical features that anticipate long-term cognitive and symptomatic decline. Here, we collected MRI, cognitive, and symptomatic data from 165 healthy controls and 357 drug-naïve or minimally medicated FEP individuals that were followed up 1,3,5 and 10 years after the first episode. (1778 MRI scans and assessments in total). Using normative modelling, we derived subject-specific centile scores for cortical volume to investigate atypical deviations in FEP and their relationship to long-term cognitive and symptomatic deterioration. The resulting centile association maps were further characterized by examining their cytoarchitectural and neurobiological attributes using normative atlases.

Aims: To investigate cortical volume longitudinal deviations in FEP using normative modelling, exploring their relationship with long-term cognitive and symptomatic outcomes, as well as their cytoarchitectural and neurobiological underpinnings.

Results: FEP centiles showed a widespread reduction at treatment initiation, with longitudinal analysis showing an increase during treatment time, indicating convergence toward normal maturation trajectories. Interestingly, this effect was reduced in highly medicated individuals. Additionally, we found that cognitive impairments experienced during early FEP stages were correlated with centiles and mitigated by time. Positive symptomatology was negatively associated with regional centiles, and individuals with higher centiles benefited most from treatment. Cytoarchitectural and neurobiological analyses revealed that regional centiles related to FEP, as well as to cognitive function, were associated with specific molecular features, such as regional serotonin receptor densities in heteromodal areas.

Conclusions: Collectively, these findings underscore the potential use of centile-based normative modelling for a better understanding of how atypical cortical development contributes to the long-term clinical progression of neurodevelopmental conditions.

INTRODUCTION

Atypical brain structure in FEP

First Episode Psychosis (FEP) is characterised by heterogeneous clinical presentations (1), temporal progression (2,3), and responses to medication (4). Cross-sectional MRI studies consistently report alterations in frontal and temporal cortices (5,6), with some identifying changes in insular (7), parietal (8), and occipital regions (9). Longitudinal studies have additionally revealed progressive cortical deterioration in FEP, especially in frontal and temporal regions, over 1 (10), 2–3 (11,12), 5 (13), and 10 years (14). Despite these findings, the complex interplay between brain development, sex, and neurodevelopmental pathophysiology complicates the disentanglement of their individual contributions to brain structure and function. Normative modelling addresses this by creating “growth charts” of brain development (15), allowing individuals to be ranked and assigned centile scores based on deviations from expected neurotypical trajectories. This approach has been used to identify abnormal structural subtypes in autism (16) and deviations in ADHD symptoms (17). In psychosis, normative modelling reveals deviations in cortical thickness in temporal areas during high-risk states (18) and across the cortex in FEP (19), with these deviations diminishing during treatment (20).

Brain structure and clinical outcomes

MRI studies have also extensively explored the clinical presentation of FEP, linking positive symptoms, such as hallucinations and delusions, to thinning in frontal (21) and temporal (22) cortices. Conversely, negative symptoms, like anhedonia and social withdrawal, are associated with reduced orbitofrontal thickness (23). The effects of antipsychotics on brain structure remain debated, with studies reporting both grey matter reductions (24) and increased regional thickness (25). Cognitive decline in FEP has been observed prior to the onset of psychosis (26,27), while post-onset trajectories vary, with reports of stabilization (28,29), decline (30), or improvement (31). Normative modelling has shown neurocognitive delays in youth reporting psychotic symptoms (32), but the long-term impact of antipsychotics on cognition remains uncertain (33).

Regional vulnerability to atypical development

The spatial patterns of cortical deterioration shared across psychiatric and neurological conditions have been interpreted as a reflection of differential regional vulnerability to pathology (34). Under this hypothesis, cortical vulnerability to psychosis-related deterioration may reflect regional differences in cellular composition, neurotransmitter receptors, and metabolism (34,35), with regions of high serotonin and acetylcholine receptor density showing greater atypical deviations (36). In this study, we hypothesize that FEP patients exhibit atypical brain development influenced by treatment and medication, which impacts cognitive and symptom progression. We analysed baseline and 10-year follow-up longitudinal data to explore associations between brain deviations, clinical diagnosis, medication, cognition, and symptoms. Using cytoarchitectonic and neurobiological atlases, we additionally characterized psychosis-related brain deviations based on neurotransmitters, cell types, microstructure, and metabolism.

METODOLOGY

Subjects

MRI and phenotypic data were collected from healthy controls (n = 143; 76 males; mean age = 29.96 ± 7.45 years) and individuals with first-episode psychosis (FEP; n = 352; 214 males; mean age = 29.71 ± 8.77 years), who were followed longitudinally. Follow-up assessments were conducted at 1 (51 controls, 106 FEP), 3 (41 controls, 149 FEP), 5 (68 controls, 56 FEP), and 10 (94 controls, 118 FEP) years.

Recruitment was conducted through the Program for Attention to the Initial Phases of Psychoses (PAFIP) at Marqués de Valdecilla University Hospital and Valdecilla Health Research Institute (IDIVAL) in Spain. Ethics approval was granted by the CEIC-Cantabria (clinical trial numbers NCT0235832 and NCT02534363). Participants in the clinical group met DSM-IV criteria for schizophrenia spectrum disorders, including schizophrenia (n=169), schizophreniform disorder (n=102), schizoaffective disorder (n=6), brief psychotic disorder (n=49), and psychosis not otherwise specified (n=26). See a full list of inclusion and exclusion criteria in Supplementary Methods. Detailed demographic and clinical information stratified by sex and diagnosis are provided in Supplemental Material (Figs. S1-S2 and Tables S1-S4).

Cognitive and symptom assessment

Cognition was assessed for the following domains: (1) verbal memory: Rey Auditory Verbal Learning Test (RAVLT) long-term recall score; (2) visual memory: Rey Complex Figure test (RCFT) long-term recall score; (3) motor dexterity: grooved pegboard (GP), time to complete with dominant hand; (4) executive functions: Trail Making Test part B (TMTb); (5) working memory: WAIS III-Backward Digits (BD) total score; (6) speed of processing: WAIS III-Digit Symbol (DS) standard total score; (7) attention: Continuous Performance Test Degraded-Stimulus (CPT-DS), the total number of correct responses (37). For each cognitive test, z-scores were computed by subtracting the mean and dividing by the standard deviation of the control group's scores. Overall cognitive functioning was calculated as the mean z-score across the seven cognitive tests for each individual. FEP participants were also assessed using the Scale for the Assessment of Negative Symptoms (SANS, 21 items), Scale for the Assessment of Positive Symptoms (SAPS, 30 items), and Brief Psychiatric Rating Scale (BPRS, 24 items).

Principal Component Analysis (PCA) was conducted on cognition and symptom items to compare with average scores used in the calculations. Sensitivity analyses examined (i) the impact of cannabis use and (ii) study dropout on cognitive and symptom measures. Psychological evaluations were performed by experienced psychiatrists using the structured clinical interview for DSM-IV, with diagnoses confirmed at 6 months.

MRI acquisition and volume extraction

Structural MRI scans were acquired using a 1.5T General Electric SIGMA System (GE, Milwaukee, USA) and a 3T Philips Medical Systems MRI scanner (Achieva, Best, The Netherlands) equipped with an 8-channel head coil. Baseline and follow-up scans for each individual were consistently conducted using the same machine. The imaging protocol included a T1-weighted image that underwent visual inspection for QC. The parameters for 1.5T were: TE=5ms, TR=24ms, NEX=2, rotation angle=45°, FOV=26×19.5cm, slice thickness=1.5mm, voxel size=1.02x1.02x1.5 mm, and a matrix of 256×192, whereas for 3T were TE = 3.7ms, TR=8.2ms, flip angle=8°, acquisition matrix=256×256, voxel size=0.94x0.94x1 mm and 160 contiguous slices. Regional volumes were computed with FreeSurfer 6.0.0's recon-all for each region defined in the Desikan-Killiany cortical parcellation (34 regions per hemisphere). Outliers (>5 SD from the mean) were excluded. Subjects were distributed across scanners as follows: GE 1.5T (28.3% FEP, 12.5% controls) and Philips 3T (39.8% FEP, 19.5% controls).

Regional volumetric centile estimation

Normative trajectories of lifespan grey matter volume (15) were used to benchmark cortical volumes from the Desikan-Killiany atlas against data from more than 100,000 neurotypical individuals (https://github.com/brainchart/Lifespan). Because these trajectories were based on hemispheric-averaged regional volumes, the same approach was applied to our dataset. Age-normed, sex-stratified, and site-corrected deviations were derived and expressed as centile scores. Centile scores indicate the relative position of an individual's grey matter volume compared with normative lifespan expectations. Values below 0.5 reflect lower-than-expected volumes, whereas values above 0.5 reflect preserved or increased volumes. Residual effects of site or motion (Euler index) on centile scores were assessed using ANOVA.

Baseline analyses using multivariate regression

To evaluate the impact of FEP diagnosis on baseline centiles, a multivariate regression was performed for each cortical region using the following model:

$$regional\ centile \sim 1 + diagnosis + sex + age\ of\ inclusion + etiv \quad (1)$$

where "diagnosis" was a binary variable (control vs. FEP), "age of inclusion" referred to participants' age at the first scan, and "etiv" represented cranial volume residuals after age and sex correction. "Age of inclusion" and "etiv" were Z-scored prior to regression. Statistical analyses were performed on 143 controls and 352 FEP subjects, with multiple comparisons corrected using False Discovery Rate (FDR).

Longitudinal analyses using Mixed Modelling

The longitudinal effects of disease and medication on centiles and clinical outcomes were analysed using Mixed Modelling over 1,178 assessments (397 controls, 781 FEP). Antipsychotic medication exposure was quantified as chlorpromazine equivalents at the time of the assessment (CPZ-equivalents) (38).

Linear Mixed Modelling for predicting regional centiles as a function of disease progression and treatment

The impact of time from the first scan (for controls) and time from treatment initiation (for FEP), collectively referred to as time, in regional centiles were assessed using Linear Mixed Modelling (LMM):

$$regional\ centile \sim 1 + diagnosis + sex + age\ at\ inclusion + etiv + medication + time{:}\ diagnosis + medication{:}\ time + (1|\ subject) \quad (2)$$

where, in addition to the aforementioned variables, we also considered: medication at the time of MRI acquisition (antipsychotic dose in CPZ-equivalents), time:diagnosis (interaction between time and diagnosis) and medication:time (interaction indicating whether medication alters the effect of treatment time on centiles) and "1|subject" as a random intercept to account for random subject-specific offsets overall. In this model, the interaction between time and diagnosis captures group-specific trajectories, allowing FEP and Control subjects to exhibit distinct slopes over time. "Age of inclusion", "etiv", "Medication" and "time" were Z-scored prior to regression.

Sensitivity analyses repeated these models using raw regional volumes instead of centiles as the dependent variable.

LMM for predicting cognitive functioning as a function of treatment and regional centiles

After exploring the effect of disease and treatment on centiles, we evaluated how these factors mediate overall cognitive functioning:

$$\begin{aligned} cognition \sim 1 + \ diagnosis + \ sex \ + \ age\ at\ inclusion \ + \ etiv + \ medication \\ + \ time{:}\,diagnosis \ \ + \ medication{:}\,time + centile{:}\,diagnosis \\ + centile{:}\,time + (1|\ subject) \qquad (3) \end{aligned}$$

where, in this case, regional centile is considered as an independent variable. Through diagnosis interaction variables, we assessed the differential impact of time and centiles on the control and FEP groups using a single model.

Generalized Mixed Modelling for predicting clinical symptomatology as a function of treatment and regional centiles

Symptomatology (BPRS, SAPS, and SANS scores) was modelled as:

$$\begin{aligned} symptoms \sim 1 + \ sex \ + age\ at\ inclusion \ + \ etiv + centile + time + \ medication \\ + medication{:}\,time + centile{:}\,medication + centile{:}\,time \\ + \ (1|\ subject) \ \ (4) \end{aligned}$$

Generalized Mixed Models with a Poisson distribution were used due to the count-like nature of symptom scores and their alignment with exponential decay patterns. Separate analyses were conducted for each psychometric scale.

Cytoarchitectural characterization of centile associations

Cortical centiles associated with phenotypic variables (diagnosis, medication, cognition, BPRS, SAPS, SANS) were mapped onto the cortical hierarchies defined by Mesulam atlas (unimodal, paralimbic, idiotypic, heteromodal, https://github.com/ucam-department-of-psychiatry/maps_and_parcs, Supplementary **Table S5,** (39)). ANOVA tests and Tukey post-hoc analyses were used to identify differential distributions of centile associations across Mesulam areas.

Neurobiological mapping of centile associations

Centile-phenotypic associations were also profiled using 46 molecular and microarchitectural maps derived from MRI/PET studies, expanding on the methodology presented on (40) and implemented at https://github.com/netneurolab/neuromaps and https://github.com/RafaelRomeroGarcia/NeurobiologyCentilesPsychosis. These maps included: neurotransmitter receptors (5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_4, 5-HTT, H_3, D_1, D_2, DAT, NET, $\alpha_4\beta_2$, VAChT, CB_1, M_1, MOR, $mGluR_5$, NMDA, GABA), cell types (astrocytes, endothelial cells, microglia, oligodendrocytes, oligodendrocytes precursors, excitatory neurons, inhibitory neurons), cortical layers (I-VI), microstructural properties (synapse density, neurotransmitter PC1, gene expression PC1 [which is highly driven by cell types (41)], cortical thickness, myelin), metabolism (glycolytic index, cerebral blood flow, cerebral blood volume, oxygen metabolism and glucose metabolism), cortical expansion (evolutionary expansion, developmental expansion, allometric scaling from Philadelphia Neurodevelopmental Cohort, allometric scaling from National Institutes of Health). See supplementary **Table S6** for the full list of neurobiological features included in the analysis.

Principal Component – Canonical Correlation Analysis (PC-CCA; https://github.com/RafaelRomeroGarcia/cca_pls_toolkit) was used to identify combinations of neurobiological features that best explained centile-phenotypic associations (42). PC-CCA reduces data dimensionality using PCA to minimize overfitting and then identifies the linear combination (weighted sum of loadings) of the neurobiological maps that best predicts the inter-regional variance of each centiles-phenotypic association map. Statistical significance was evaluated using spatial autocorrelation-preserving permutation tests (spin tests; https://github.com/frantisekvasa/rotate_parcellation (43)) with 10,000 parcellation-specific rotations. To validate the multivariate patterns identified with PC-CCA, we conducted a sensitivity analysis with Partial Least Squares (PLS). PLS maximizes the covariance between the two variable sets, providing a robust alternative when collinearity might affect the canonical solution (42).

RESULTS

Impact of diagnosis and treatment on centiles

Using multivariate linear regression on baseline data, FEP patients demonstrated significantly lower total grey matter volume centiles compared to controls ($t = -2.64$, $p = 0.0085$), but no reductions in total white matter centiles ($t = -0.04$, $p = 0.97$; **Table S7**). Consistently, regional analyses showed widespread cortical reductions in centiles associated with diagnosis (**Fig. 1**, Baseline). Covariates such as age at inclusion and etiv correlated positively with centiles, while females exhibited lower centiles (**Fig. 1**, Baseline). Effect sizes and FDR-corrected significance levels are fully provided in the supplementary data. Centiles were not significantly associated with motion artifacts quantified using the Euler index (Spearman's rho = -0.016, $p = 0.587$; **Fig. S3**).

Longitudinal analyses using LMM over 10 years revealed that longer treatment duration in FEP patients was associated with increased global centile scores, progressively approaching normative values ($t = 5.3$, $p < 10^{-6}$; **Table S8**), whereas controls showed no time-dependent association ($t = -0.3$, $p = 0.75$). Regionally, significant diagnosis-centile associations were observed in the pars orbitalis, superior temporal, transverse temporal, and lateral occipital areas (**Fig. 1**, Longitudinal). Medication (CPZ-equivalent) was negatively associated with centiles in temporal and frontal regions. Centiles increased with time in FEP but not in control (see **Fig. S4A** for an illustration of this interaction), however, this was attenuated in individuals with higher medication doses.

These LMM analyses were repeated using raw volumes instead of centiles. As shown in **Fig. S5**, age-related reductions of regional volume dominated all interaction effects, masking the separate trajectories in controls and FEP described by the centile approach.



Fig. 1. Associations between phenotypic data and covariates with regional centiles. **Top panel.** Contribution of each variable to the multivariate regression of baseline data. **Bottom panel** Contribution of each variable to the LMM of longitudinal changes in centiles (up to 10 years follow-up). Scale represents t-values associated with each regression parameter. Non-significant contributions (P_{fdr} ≥0.05) are depicted with desaturated colours.

Regional centiles associated with cognitive impairment

Principal component analysis (PCA) of cognitive subscales revealed a first PC explaining 45.3% of the variance, with similar weights across the seven subscales (Table S9), so for simplicity, the mean score was used in subsequent analyses. Cognitive function was negatively associated with FEP diagnosis (**Fig. 2**, diagnosis) and correlated extensively with regional centiles in FEP, but not in controls, indicating that cognitive impairment is linked to atypical volume development in psychosis (**Fig. 2**, centile - diagnosis interaction). This differential association is

273 illustrated for a representative region in **Fig. S4B**. Time positively influenced cognitive function
274 in FEP but not in controls. Negative interaction between medication and time indicates that
275 cognitive improvement is reduced in highly medicated patients (illustrated in **Fig. S24C**). Other
276 covariates showed either a negative (age of inclusion) or no association (sex, etiv, medication,
277 centile-time interaction) with cognition.



278

279 **Fig. 2.** Associations between phenotypic data, covariates and centiles with cognitive
280 performance. Contribution of each variable to the LMM of longitudinal changes in cognition
281 (up to 10 years follow-up). Scale represents t-values associated with each regression
282 parameter. Non-significant contributions ($P_{fdr} \geq 0.05$) are depicted with desaturated.

Regional centiles associated with symptomatology

Treatment time correlated negatively with BPRS, SAPS, and SANS scores, suggesting symptom reduction over time (**Fig. 3**). Medication was associated with reductions in BPRS and SAPS scores but increased SANS scores, likely due to pharmacological specificity for positive symptoms. A positive medication-time interaction indicates that symptom improvement with time were less pronounced in highly medicated patients. Positive symptoms (SAPS) were negatively associated with centiles, particularly overlapping with BPRS, whereas SANS showed no centile correlation. Younger age at onset was linked to more severe positive symptoms (SAPS).

No significant differences were observed in cognitive or symptom scores between cannabis users and non-users (**Table S10**) or between participants who completed the study and those who dropped out (**Table S11**).



Fig. 3. Associations between phenotypic data, covariates and centiles with symptomatology. Contribution of each variable to the GMM of longitudinal changes in BPRS, SAPS and SANS (each column represent different models). Scale represents the Wald z-statistic associated with each regression parameter. Non-significant contributions ($P_{fdr} \geq 0.05$) are depicted with desaturated colours.

Cytoarchitectural and neurobiological characterization of FEP-related regional centiles

Using the Mesulam cytoarchitectonic atlas (39), we characterized regional associations between centiles, treatment, cognition, and symptoms. Centiles related to cognitive function in FEP were predominantly located in unimodal, paralimbic, and heteromodal cortices, compared to idiotypic cortex (**Fig. 4A**). Conversely, the association between centiles and BPRS and SANS was more negative in heteromodal areas than in paralimbic. Finally, the correlation between centiles and SAPS scale was significantly more negative in paralimbic cortex than in unimodal cortex (all ANOVA, Post-hoc Tukey, P_{fdr} <0.05). No preferential location was identified for centiles associated with cognitive function in control participants.

PCA-CCA was used to capture associations between neurobiological data from normative individuals (40) and centiles related to clinical outcomes. Neurobiological mapping revealed that regions associated with FEP diagnosis (Fig. 1) co-located with areas rich in neurotransmitters such as 5-HT_{1B}, 5-HT_{2A}, M_1, and NMDA, as well as neurons and metabolic features (**Fig. 4B**, negative loadings). Conversely, FEP diagnosis-related regions were associated with lower glial cell densities and 5-HT_{1A} neurotransmitter levels (positive loadings). Similarly, regions negatively impacted by medication were linked to high concentrations of 5-HT_{1A}, 5-HT_4, CB_1, D_2, NET, and glial cells, as well as layers I, II, III, and VI thickness.

Centiles associated with cognitive function in FEP were co-located in areas rich in 5-HT_{2A}, 5-HT_4, $\alpha_4\beta_2$, CB1, MOR, and NET, as well as synapse density and metabolic markers such as CBF, CBV, and CMRGlu (**Fig. 4C**). Control participant analyses revealed no significant co-locations, suggesting specificity to FEP. Neurobiological associations with symptoms showed similarities for BPRS and SANS (SAPS model was not significant), with neurotransmitter correlations (positive for 5-HT_{1A}, 5-HTT, and D_2; negative for 5-HT_{1B}, 5-HT_{2A}, NMDA) and cellular features (positive for glia, negative for neurons). They also show differences in $\alpha_4\beta_2$, GABA, M1 and CMRGlu (for BPRS) and in NET receptors and thickness of layer III (for SANS).

Collectively, these results reveal a significant co-location of atypical brain maturation in FEP with specific neurobiological factors, suggesting that they may play an important role in shaping the structural vulnerability to FEP symptomatology. Consistency analyses using PLS instead of PCA-CCA yielded highly similar neurobiological loading estimates (all r-values > 0.98; **Fig. S6**).



Fig. 4. Cytoarchitectural and neurobiological characterisation of FEP-related centiles. **A)** Distribution of t-values shown in Figs. 2 and 3 across the four cortices delineated in the atlas of Mesulam. Each dot represents a brain region in the Desikan-Killiany atlas. **B)** Neurobiological maps co-located with the diagnosis-centile and medication-centile associations. Positive loadings indicate neurobiological features that are co-located with regions where centiles were positively associated with the variables of interest (in this case, diagnosis and medication). Conversely, negative loadings indicate co-location with regions negatively associated with the variable of interest. **C)** Neurobiological maps co-located with the association between centiles

and clinical outcomes (cognitive function, BPRS SAPS, and SANS). “N.S.” denotes non-significant models ($P_{fdr} \geq 0.05$). For significant models, only significant ($P_{fdr} < 0.05$) loadings are displayed.

DISCUSSION

In this study, we examined cortical volume deviations using normative centiles models in both neurotypical and FEP participants scanned over the course of 10 years. Our findings indicated that FEP participants had lower regional centiles than controls in multiple cortical areas, a difference that decreased in intensity over the treatment period. However, this convergence between patients and controls was less pronounced in those who were highly medicated. Cognitive functioning in FEP was positively correlated with centiles co-located with regions with high serotonin receptor densities. These results highlight the value of normative approaches for better understanding the long-term relationship between cortical maturation and clinical profiles in psychosis.

Our normative analysis revealed atypical developmental values in FEP patients who exhibited a generalised reduction in regional cortical volume centile scores (19). Previous studies have extensively reported reductions in cortical volume and thickness at different stages of psychosis-related conditions (7,9,19,44). As shown by the ENIGMA consortium, although frontal and temporal cortices are the regions showing the strongest effect sizes when compared to normative controls, schizophrenia is also characterised by a generalised reduction over the whole cortex (45). Nevertheless, a major challenge in traditional case-control studies is the lack of personalised metrics capable of detecting individuals with atypical neurodevelopment. Conversely, normative modelling leverages data from thousands of individuals for identifying participants with abnormal trajectories. Using this approach, Worker et al. 2023 (19), demonstrated that a large and widespread number of extreme negative deviations in cortical thickness centiles among FEP exist, revealing that this condition is characterised not only by a diminished group-average cortical thickness but also by specific individuals that exhibit severe thickness reductions.

The combination of normative modelling with long-term longitudinal MRI revealed that centiles increased during the treatment period of FEP participants. These findings suggest that grey matter reductions are more severe during the early stages of psychosis (46), and the differences between the FEP and control groups decrease over time (25,47,48) . Berthet et al. (2025) (20) also reported this trend toward a reduced difference over time between controls and FEP patients when investigating cortical thickness using normative modelling. Since this

374 study did not include untreated patients, we cannot disentangle the specific effects of
375 treatment from the natural progression of the disease.

376 The progressive convergence of centiles to the expected normative values during treatment
377 might suggest that the drugs elicit neuroplasticity in FEP patients, however, potential late
378 effects of neurodegenerative pathogenesis cannot be discarded (49). Importantly, as most
379 participants were prescribed with antipsychotic drugs, we cannot fully untangle the causal role
380 of medication in cortical volume reductions. Medication has been previously associated with
381 grey matter loss (50), specifically attributed to caspase-3-mediated neurotoxicity (51,52). In
382 this line, we also found that individuals on high medication doses did not show a generalized
383 cortical reduction effect, but rather exhibited localized reductions in the temporal and frontal
384 areas. As suggested by Fusar-Poli et al. 2013 metanalysis (53), long-term GM reductions may be
385 the consequence of the cumulative exposure to the antipsychotics, a finding also supported by
386 other studies (24,54).

387 While describing the anatomical alterations related to the progression and treatment of
388 psychosis is of great interest, understanding how these changes impact patients' cognitive
389 functionality is of crucial clinical importance. We reported reduced cognitive abilities in drug-
390 naïve and minimally medicated FEP participants immediately after the onset, suggesting that
391 impairment occurs even before the first episode (26,55,56). Cognitive functionality also
392 improved throughout the treatment period, indicating that while medication targets positive
393 symptoms, it may also lead to cognitive improvement, albeit as an indirect effect. (26).
394 Previous studies have also demonstrated cognitive improvement in patients after one (11) or
395 three (57) years of antipsychotic treatment. Nevertheless, our LMM additionally found that
396 medication played a mediating role in the association between treatment duration and
397 cognitive function, leading to an attenuation of cognitive recovery over time for patients with
398 higher medication doses. In line with this observation, Kawai et al. 2006 (58) demonstrated
399 that dose-reductions lead to improvements in cognitive performance in a limited sample of
400 individuals treated with multiple conventional antipsychotics. In addition to treatment
401 duration, the other factor showing a positive relation with cognitive function was regional
402 centiles which aligns with the associations between cognition and structural features such
403 volume and thickness described in previous non-normative FEP studies (8,59–62).

404 Similar to cognitive progression, treatment yielded a positive effect on FEP-related
405 symptomatology. As expected, both time and medication primarily had an impact on positive
406 symptoms. Conversely, time had a positive but weaker effect on the reduction of negative

407 symptoms. Despite the fact that medication, especially first-generation antipsychotics, does
408 not alleviate negative symptoms, meta-analyses of placebo-control trials have indeed revealed
409 that most treatments can help reduce negative symptomatology (63). Nevertheless, here, we
410 observed opposite trends in the model slopes of time (negative) and medication (positive) with
411 SANS, indicating that heavily medicated individuals do not experience negative symptoms
412 improvements over time. This may reflect the diverse and distinct recovery trajectories of
413 illness, with a significant proportion of patients experiencing relapse and showing no
414 improvement in negative symptoms (64). FEP symptomatology was also associated with
415 regional volumes, with higher centiles values generally associated with lower positive
416 symptoms. Similarly, previous studies have associated positive symptoms with cortical
417 alterations in prefontal, temporal and parietal areas (22). Conversely, negative symptoms
418 exhibited no correlation with centiles, suggesting that while treatment and medication may
419 provide moderate improvement in this domain, these symptoms remain relatively stable and
420 do not significantly influence cortical plasticity. However, further placebo-controlled trials will
421 be necessary to elucidate this (64).

422 Centiles related with different aspects of FEP were co-located with regions with specific
423 microarchitectural and neurobiological features. Microarchitecturally, cognitive functioning was
424 associated with centiles preferentially located in association (heteromodal, unimodal) and
425 paralimbic cortices rather than idiotypic (primary) regions. Extensive literature has highlighted
426 the crucial role of heteromodal and paralimbic regions in higher-order cognitive functioning,
427 specifically linking these regions to cognitive decline in psychosis (65–67). Neurobiologically,
428 serotonin neurotransmitters were predominantly present in regions associated with psychosis
429 diagnosis, medication and cognitive functioning. This may be related with the role of this
430 neurotransmitter mediating the effect of antipsychotic medication which affects mood and
431 cognitive function (68). We also reported differences in centile associations across receptor
432 subtypes such as $5HT_{1A}$ and $5HT_{2A}$ which could be a reflection of its complex role in psychosis
433 (69,70). Additionally, the high density of dopamine receptors in regions associated with
434 medication suggests a potential pathway whereby elevated levels of antipsychotic medications
435 disproportionately affect dopaminergic regions. Moreover, diagnosis and symptom-related
436 centiles were not only associated with neuronal density maps but also with glial cells,
437 indicating a potential involvement of immunological and inflammatory risk factors (71–73).

438 **Limitations**

Several limitations must be acknowledged. Firstly, the primary inclusion criterion was the diagnosis of FEP at baseline, regardless of subsequent follow-up diagnoses, which predominantly included schizophrenia but also other psychotic disorders. Secondly, medication was standardized as chlorpromazine equivalents to simplify analysis and reduce model overfitting. However, this approach fails to capture the specific effects of different medications. Finally, higher medication doses were generally prescribed to individuals with more resistant positive symptoms. However, these prescriptions were influenced by factors such as age of onset and treatment duration, complicating the disentanglement of individual contributions in the models.

Conclusions

This study applied a normative modelling approach to demonstrate that FEP is associated with regional decreases in cortical centiles, with partial reversal over time in low-medicated individuals. Improvements in cognitive abilities and symptomatology were positively associated with time. Additionally, individuals with centiles closer to normative values exhibited better cognitive performance and less severe positive symptoms. Regions sensitive to cognitive function and symptomatology co-located with higher serotonin receptor densities and other neurobiological features. Collectively, these findings provide critical insights into the long-term interactions between cortical structure, treatment, medication, cognitive function, and symptom profiles.

Data and Code availability

All code and non-clinical data used to perform the analyses can be found at https://github.com/RafaelRomeroGarcia/LongitudinalCentilesFEP/. Data from patients is available upon request in accordance with ethical regulations. All statistical results are provided in a supplementary Excel file.

Acknowledgements

We thank Agoston Mihalik, Golia Shafiei, Bratislav Misic, Victor Ortiz and Lifespan Brain Chart Consortium for their contribution.

Funding

RRG is funded by the EMERGIA Junta de Andalucía program (EMERGIA20_00139), the *Plan Propio* of the University of Seville and the Plan de Consolidación (CNS2023-143647). Both RRG

and CAM, are funded by the *Plan de Generación de Conocimiento* from the Agencia Estatal de Investigación (PID2021-122853OA-I00).

Competing interests

RAIB and JS hold equity in and are directors of Centile Bioscience. All other authors declare that they have no known competing interests.

REFERENCES

1. Voineskos AN, Jacobs GR, Ameis SH. Neuroimaging Heterogeneity in Psychosis: Neurobiological Underpinnings and Opportunities for Prognostic and Therapeutic Innovation. Biological Psychiatry. 1 de julio de 2020;88(1):95-102.

2. Prakash J, Chatterjee K, Srivastava K, Chauhan VS. First-episode psychosis: How long does it last? A review of evolution and trajectory. Ind Psychiatry J. 2021;30(2):198-206.

3. Gaebel W, Zielasek J. Focus on psychosis. Dialogues Clin Neurosci. marzo de 2015;17(1):9-18.

4. Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. AJP. abril de 2020;177(4):342-53.

5. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet. 25 de enero de 2003;361(9354):281-8.

6. Oertel-Knöchel V, Knöchel C, Rotarska-Jagiela A, Reinke B, Prvulovic D, Haenschel C, et al. Association between Psychotic Symptoms and Cortical Thickness Reduction across the Schizophrenia Spectrum. Cerebral Cortex. 1 de enero de 2013;23(1):61-70.

7. Crespo-Facorro B. Insular cortex abnormalities in schizophrenia: a structural magnetic resonance imaging study of first-episode patients. Schizophrenia Research. 30 de noviembre de 2000;46(1):35-43.

8. Yildiz M, Borgwardt SJ, Berger GE. Parietal Lobes in Schizophrenia: Do They Matter? Schizophr Res Treatment. 2011;2011:581686.

9. Tordesillas-Gutierrez D, Ayesa-Arriola R, Delgado-Alvarado M, Robinson JL, Lopez-Morinigo J, Pujol J, et al. The right occipital lobe and poor insight in first-episode psychosis. PLoS One. 2018;13(6):e0197715.

10. Del Re EC, Stone WS, Bouix S, Seitz J, Zeng V, Guliano A, et al. Baseline Cortical Thickness Reductions in Clinical High Risk for Psychosis: Brain Regions Associated with Conversion to Psychosis Versus Non-Conversion as Assessed at One-Year Follow-Up in the Shanghai-At-Risk-for-Psychosis (SHARP) Study. Schizophr Bull. 16 de marzo de 2021;47(2):562-74.

11. Zipparo L, Whitford TJ, Redoblado Hodge MA, Lucas S, Farrow TFD, Brennan J, et al. Investigating the neuropsychological and neuroanatomical changes that occur over the first 2-3 years of illness in patients with first-episode schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 15 de febrero de 2008;32(2):531-8.

12. Cobia DJ, Smith MJ, Wang L, Csernansky JG. Longitudinal progression of frontal and temporal lobe changes in schizophrenia. Schizophrenia Research. 1 de agosto de 2012;139(1):1-6.

13. van Haren NEM, Hulshoff Pol HE, Schnack HG, Cahn W, Mandl RCW, Collins DL, et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology. octubre de 2007;32(10):2057-66.

14. Rodriguez-Perez N, Ayesa-Arriola R, Ortiz-García de la Foz V, Setien-Suero E, Tordesillas-Gutierrez D, Crespo-Facorro B. Long term cortical thickness changes after a first episode of non- affective psychosis: The 10 year follow-up of the PAFIP cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 8 de junio de 2021;108:110180.

15. Bethlehem RAI, Seidlitz J, White SR, Vogel JW, Anderson KM, Adamson C, et al. Brain charts for the human lifespan. Nature. 21 de abril de 2022;604(7906):525-33.

16. Shan X, Uddin LQ, Xiao J, He C, Ling Z, Li L, et al. Mapping the Heterogeneous Brain Structural Phenotype of Autism Spectrum Disorder Using the Normative Model. Biological Psychiatry. 1 de junio de 2022;91(11):967-76.

17. Marquand AF, Rezek I, Buitelaar J, Beckmann CF. Understanding Heterogeneity in Clinical Cohorts Using Normative Models: Beyond Case-Control Studies. Biological Psychiatry. 1 de octubre de 2016;80(7):552-61.

18. ENIGMA Clinical High Risk for Psychosis Working Group. Normative Modeling of Brain Morphometry in Clinical High Risk for Psychosis. JAMA Psychiatry. 1 de enero de 2024;81(1):77-88.

19. Worker A, Berthert P, Lawrence AJ, Kia SM, Arango C, Dinga R, et al. Extreme deviations from the normative model reveal cortical heterogeneity and associations with negative symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies. Transl Psychiatry. 2 de diciembre de 2023;13(1):1-9.

20. Berthet P, Haatveit BC, Kjelkenes R, Worker A, Kia SM, Wolfers T, et al. A 10-Year Longitudinal Study of Brain Cortical Thickness in People with First-Episode Psychosis Using Normative Models. Schizophrenia Bulletin. 20 de diciembre de 2024;51(1):95-107.

21. Padmanabhan JL, Tandon N, Haller CS, Mathew IT, Eack SM, Clementz BA, et al. Correlations Between Brain Structure and Symptom Dimensions of Psychosis in Schizophrenia, Schizoaffective, and Psychotic Bipolar I Disorders. Schizophrenia Bulletin. 1 de enero de 2015;41(1):154-62.

22. Walton E, Hibar DP, van Erp TG, Potkin SG, Roiz-Santiañez R, Crespo-Facorro B, et al. Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA-Schizophrenia consortium. Acta Psychiatr Scand. mayo de 2017;135(5):439-47.

23. Walton E, Hibar DP, van Erp TGM, Potkin SG, Roiz-Santiañez R, Crespo-Facorro B, et al. Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortium. Psychol Med. enero de 2018;48(1):82-94.

24. Vita A, De Peri L, Deste G, Barlati S, Sacchetti E. The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies. Biol Psychiatry. 15 de septiembre de 2015;78(6):403-12.

25. Goghari VM, Smith GN, Honer WG, Kopala LC, Thornton AE, Su W, et al. Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naïve first-episode psychosis patients. Schizophrenia Research. 1 de septiembre de 2013;149(1):149-55.

26. Bora E, Murray RM. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? Schizophr Bull. julio de 2014;40(4):744-55.

27. Lecardeur L, Meunier-Cussac S, Dollfus S. [Cognitive deficits in first episode psychosis patients and people at risk for psychosis: from diagnosis to treatment]. Encephale. mayo de 2013;39 Suppl 1:S64-71.

28. Rund BR, Barder HE, Evensen J, Haahr U, Hegelstad W ten V, Joa I, et al. Neurocognition and Duration of Psychosis: A 10-year Follow-up of First-Episode Patients. Schizophr Bull. enero de 2016;42(1):87-95.

29. McCleery A, Nuechterlein KH. Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations. Dialogues Clin Neurosci. septiembre de 2019;21(3):239-48.

30. Fett AKJ, Velthorst E, Reichenberg A, Ruggero CJ, Callahan JL, Fochtmann LJ, et al. Long-term Changes in Cognitive Functioning in Individuals With Psychotic Disorders: Findings From the Suffolk County Mental Health Project. JAMA Psychiatry. 1 de abril de 2020;77(4):387-96.

31. Burgher B, Scott J, Cocchi L, Breakspear M. Longitudinal changes in neural gain and its relationship to cognitive control trajectory in young adults with early psychosis. Transl Psychiatry. 3 de marzo de 2023;13(1):1-9.

32. Gur RC, Calkins ME, Satterthwaite TD, Ruparel K, Bilker WB, Moore TM, et al. Neurocognitive Growth Charting in Psychosis Spectrum Youths. JAMA Psychiatry. 1 de abril de 2014;71(4):366-74.

33. Husa AP, Moilanen J, Murray GK, Marttila R, Haapea M, Rannikko I, et al. Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort. Psychiatry Res. enero de 2017;247:130-8.

34. Hettwer MD, Larivière S, Park BY, van den Heuvel OA, Schmaal L, Andreassen OA, et al. Coordinated cortical thickness alterations across six neurodevelopmental and psychiatric disorders. Nat Commun. 11 de noviembre de 2022;13(1):6851.

35. Hansen JY, Shafiei G, Vogel JW, Smart K, Bearden CE, Hoogman M, et al. Local molecular and global connectomic contributions to cross-disorder cortical abnormalities. Nature Communications. 10 de agosto de 2022;13(1):4682.

36. García-San-Martín N, Bethlehem RA, Mihalik A, Seidlitz J, Sebenius I, Alemán-Morrillo C, et al. Molecular and micro-architectural mapping of abnormal gray matter developmental trajectories in psychosis [Internet]. medRxiv; 2023 [citado 14 de mayo de 2024]. p. 2023.12.11.23299652. Disponible en: https://www.medrxiv.org/content/10.1101/2023.12.11.23299652v1

37. Rodríguez-Sánchez JM, Setién-Suero E, Suárez-Pinilla P, Son JMV, Vázquez-Bourgon J, López PG, et al. Ten-year course of cognition in first-episode non-affective psychosis patients: PAFIP cohort. Psychological Medicine. marzo de 2022;52(4):770-9.

38. Danivas V, Venkatasubramanian G. Current perspectives on chlorpromazine equivalents: Comparing apples and oranges! Indian J Psychiatry. 2013;55(2):207-8.

39. Mesulam MM, Mesulam MM, editores. Principles of behavioral and cognitive neurology. 2. ed. Oxford: Oxford Univ. Press; 2000. 540 p.

40. Hansen JY, Shafiei G, Markello RD, Smart K, Cox SML, Nørgaard M, et al. Mapping neurotransmitter systems to the structural and functional organization of the human neocortex. Nat Neurosci. noviembre de 2022;25(11):1569-81.

41. Dear R, Wagstyl K, Seidlitz J, Markello RD, Arnatkevičiūtė A, Anderson KM, et al. Cortical gene expression architecture links healthy neurodevelopment to the imaging, transcriptomics and genetics of autism and schizophrenia. Nat Neurosci. junio de 2024;27(6):1075-86.

42. Mihalik A, Chapman J, Adams RA, Winter NR, Ferreira FS, Shawe-Taylor J, et al. Canonical Correlation Analysis and Partial Least Squares for Identifying Brain-Behavior Associations: A Tutorial and a Comparative Study. Biol Psychiatry Cogn Neurosci Neuroimaging. noviembre de 2022;7(11):1055-67.

43. Váša F, Seidlitz J, Romero-Garcia R, Whitaker KJ, Rosenthal G, Vértes PE, et al. Adolescent Tuning of Association Cortex in Human Structural Brain Networks. Cereb Cortex. 1 de enero de 2018;28(1):281-94.

44. Gallardo-Ruiz R, Crespo-Facorro B, Setién-Suero E, Tordesillas-Gutierrez D. Long-Term Grey Matter Changes in First Episode Psychosis: A Systematic Review. Psychiatry Investig. mayo de 2019;16(5):336-45.

45. Thompson PM, Jahanshad N, Ching CRK, Salminen LE, Thomopoulos SI, Bright J, et al. ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health and disease across more than 40 countries. Transl Psychiatry. 20 de marzo de 2020;10(1):100.

46. Pantelis C, Yücel M, Wood SJ, Velakoulis D, Sun D, Berger G, et al. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr Bull. julio de 2005;31(3):672-96.

47. Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychological Medicine. noviembre de 2009;39(11):1763-77.

48. Kim NR, Park SW, Lee JG, Kim YH. Protective effects of olanzapine and haloperidol on serum withdrawal-induced apoptosis in SH-SY5Y cells. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1 de abril de 2008;32(3):633-42.

49. Woods BT. Is Schizophrenia a Progressive Neurodevelopmental Disorder? Toward a Unitary Pathogenetic Mechanism. AJP. diciembre de 1998;155(12):1661-70.

50. Haijma SV, Van Haren N, Cahn W, Koolschijn PCMP, Hulshoff Pol HE, Kahn RS. Brain Volumes in Schizophrenia: A Meta-Analysis in Over 18 000 Subjects. Schizophrenia Bulletin. 1 de septiembre de 2013;39(5):1129-38.

51. Gassó P, Mas S, Molina O, Bernardo M, Lafuente A, Parellada E. Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 10 de enero de 2012;36(1):71-7.

52. Dean CE. Antipsychotic-associated neuronal changes in the brain: Toxic, therapeutic, or irrelevant to the long-term outcome of schizophrenia? Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1 de marzo de 2006;30(2):174-89.

53. Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev. septiembre de 2013;37(8):1680-91.

54. Zipursky RB, Reilly TJ, Murray RM. The Myth of Schizophrenia as a Progressive Brain Disease. Schizophrenia Bulletin. noviembre de 2013;39(6):1363-72.

55. Becker HE, Nieman DH, Wiltink S, Dingemans PM, van de Fliert JR, Velthorst E, et al. Neurocognitive functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration? Psychol Med. octubre de 2010;40(10):1599-606.

56. Dickson H, Laurens KR, Cullen AE, Hodgins S. Meta-analyses of cognitive and motor function in youth aged 16 years and younger who subsequently develop schizophrenia. Psychol Med. abril de 2012;42(4):743-55.

57. Zabala A, Eguiluz JI, Segarra R, Enjuto S, Ezcurra J, Elizagarate E, et al. Course of cognitive functioning in first-episode psychosis: a comparison between schizophrenia and non schizophrenia psychosis. Rev Psiquiatr Salud Ment. diciembre de 2008;1(1):18-25.

58. Kawai N, Yamakawa Y, Baba A, Nemoto K, Tachikawa H, Hori T, et al. High-dose of multiple antipsychotics and cognitive function in schizophrenia: The effect of dose-reduction. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 30 de agosto de 2006;30(6):1009-14.

59. Tronchin G, Akudjedu TN, Kenney JP, McInerney S, Scanlon C, McFarland J, et al. Cognitive and Clinical Predictors of Prefrontal Cortical Thickness Change Following First-Episode of Psychosis. Psychiatry Research: Neuroimaging. 30 de agosto de 2020;302:111100.

60. Zhang X, Yao J, Lv Y, Zhao X, Li Y, Sui Y, et al. An Association Study on the Cognitive Function and the Cerebral Grey Matter Volume of Patients with First-Episode Schizophrenia. Shanghai Arch Psychiatry. 25 de junio de 2018;30(3):154-67.

61. Shen X, Jiang F, Fang X, Yan W, Xie S, Zhang R. Cognitive dysfunction and cortical structural abnormalities in first-episode drug-naïve schizophrenia patients with auditory verbal hallucination. Front Psychiatry. 2022;13:998807.

62. Gutiérrez-Galve L, Wheeler-Kingshott CAM, Altmann DR, Price G, Chu EM, Leeson VC, et al. Changes in the Frontotemporal Cortex and Cognitive Correlates in First-Episode Psychosis. Biol Psychiatry. 1 de julio de 2010;68(1):51-60.

63. Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, et al. Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophr Bull. julio de 2015;41(4):892-9.

64. Austin SF, Mors O, Budtz-Jørgensen E, Secher RG, Hjorthøj CR, Bertelsen M, et al. Long-term trajectories of positive and negative symptoms in first episode psychosis: A 10 year follow-up study in the OPUS cohort. Schizophrenia Research. 1 de octubre de 2015;168(1):84-91.

65. Stan AD, Tamminga CA, Han K, Kim JB, Padmanabhan J, Tandon N, et al. Associating Psychotic Symptoms with Altered Brain Anatomy in Psychotic Disorders Using Multidimensional Item Response Theory Models. Cereb Cortex. mayo de 2020;30(5):2939-47.

66. Pearlson GD, Petty RG, Ross CA, Tien AY. Schizophrenia: a disease of heteromodal association cortex? Neuropsychopharmacology. enero de 1996;14(1):1-17.

67. Liao J, Yan H, Liu Q, Yan J, Zhang L, Jiang S, et al. Reduced paralimbic system gray matter volume in schizophrenia: Correlations with clinical variables, symptomatology and cognitive function. J Psychiatr Res. junio de 2015;65:80-6.

68. Grinchii D, Dremencov E. Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders. Int J Mol Sci. 15 de diciembre de 2020;21(24):9532.

69. Celada P, Puig MV, Amargós-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. julio de 2004;29(4):252-65.

70. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. octubre de 2003;27(7):1159-72.

71. Bernstein HG, Steiner J, Guest PC, Dobrowolny H, Bogerts B. Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy. Schizophr Res. enero de 2015;161(1):4-18.

72. Goudriaan A, de Leeuw C, Ripke S, Hultman CM, Sklar P, Sullivan PF, et al. Specific glial functions contribute to schizophrenia susceptibility. Schizophr Bull. julio de 2014;40(4):925-35.

73. Almeida PGC, Nani JV, Oses JP, Brietzke E, Hayashi MAF. Neuroinflammation and glial cell activation in mental disorders. Brain Behav Immun Health. febrero de 2020;2:100034.